William Steere - Zoetis Independent Director
| ZTS Stock | USD 153.11 1.17 0.77% |
Director
Mr. William C. Steere, Jr. is Independent Director of the Company. Mr. Steere joined Pfizer in 1959 and held various positions, including Chief Executive Officer from 1991 until 2000, Chairman of the board of directors from 1992 until 2001, and member of the board of directors until 2011. Mr. Steere also served on the boards of Dow Jones Company, Inc. until 2007 MetLife, Inc. until 2010 and Health Management Associates, Inc. until 2014. Mr. Steeres business and senior management experience, his public company board experience and his knowledge of the animal health business obtained through his service with Pfizer make him a valuable member of our Board. since 2013.
| Age | 83 |
| Tenure | 11 years |
| Address | 10 Sylvan Way, Parsippany, NJ, United States, 07054 |
| Phone | 973 822 7000 |
| Web | https://www.zoetis.com |
Zoetis Management Efficiency
The company has Return on Asset of 0.1315 % which means that on every $100 spent on assets, it made $0.1315 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.4982 %, implying that it generated $0.4982 on every 100 dollars invested. Zoetis' management efficiency ratios could be used to measure how well Zoetis manages its routine affairs as well as how well it operates its assets and liabilities. Return On Assets is likely to gain to 0.17 in 2024, whereas Return On Tangible Assets are likely to drop 0.12 in 2024. At this time, Zoetis' Intangible Assets are comparatively stable compared to the past year. Net Tangible Assets is likely to gain to about 336.9 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 5.6 B in 2024.Similar Executives
| Found 14 records | DIRECTOR Age | ||
| Rory Riggs | Intracellular Th | 65 | |
| Tracy Marshbanks | ANI Pharmaceuticals | 52 | |
| David Nash | ANI Pharmaceuticals | 62 | |
| Patrick Walsh | ANI Pharmaceuticals | 57 | |
| Peter Lankau | ANI Pharmaceuticals | 60 | |
| Fred Holubow | ANI Pharmaceuticals | 77 | |
| Michael Rawlins | Intracellular Th | 72 | |
| Joel Marcus | Intracellular Th | 70 | |
| Christopher Alafi | Intracellular Th | 54 | |
| Thomas Haughey | ANI Pharmaceuticals | 54 | |
| Thomas Penn | ANI Pharmaceuticals | 72 | |
| Daniel Raynor | ANI Pharmaceuticals | 56 | |
| Richard Lerner | Intracellular Th | 79 | |
| Robert Nostrand | Intracellular Th | 61 | |
Management Performance
Zoetis Inc Leadership Team
Elected by the shareholders, the Zoetis' board of directors comprises two types of representatives: Zoetis inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Zoetis. The board's role is to monitor Zoetis' management team and ensure that shareholders' interests are well served. Zoetis' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Zoetis' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Roman Trawicki, Executive Vice President and Presidentident of Global Manufacturing and Supply | ||
| Steven Frank, Vice Relations | ||
| Kristin Peck, Chief Executive Officer, Executive Vice President and Group President, U.S. Operations, Business Development and Strategy, Director | ||
| Wafaa Mamilli, Executive Vice President and Chief Information and Digital Officer | ||
| William Steere, Independent Director | ||
| Roxanne Lagano, Chief Human Resource Officer, Executive Vice President and Global Operations | ||
| Linda Rhodes, Independent Director | ||
| Timothy Bettington, Executive Vice President and President U.S. Operations | ||
| Ester Banque, Executive Operations | ||
| Frank DAmelio, Independent Director | ||
| Robert Scully, Independent Director | ||
| Clinton Lewis, Executive Vice President and Group President, International Operations, Commercial Development, Global Genetics, Aquatic Health and Human Medical Diagnostics | ||
| Stefan Weiskopf, Executive Vice President and Area President of the Asia Pacific, Australia and New Zealand | ||
| Sherry Pudloski, Executive Vice President - Corporate Affairs and Communications | ||
| Sanjay Khosla, Independent Director | ||
| Paul Herendeen, CFO and Executive VP | ||
| William Price, VP Officer | ||
| Jamie Brannan, Executive Diagnostics | ||
| Catherine Knupp, Executive Vice President, President - Research and Development | ||
| Jeannette Astorga, Executive Officer | ||
| Michael McCallister, Non-Executive Independent Chairman of the Board | ||
| Paul Bisaro, Independent Director | ||
| Antoinette Leatherberry, Independent Director | ||
| Nick Ashton, Executive Supply | ||
| Alejandro Bernal, Executive Vice President and Area President of the Europe, Africa and Middle East region | ||
| Willie Reed, Independent Director | ||
| William Dorsey, Vice Diagnostics | ||
| Joyce Lee, Executive Vice President and Area President of the Canada and Latin America region | ||
| Rimma Driscoll, Commercial Strategy | ||
| Glenn David, Chief Financial Officer, Executive Vice President | ||
| Wetteny Joseph, Chief Financial Officer, Executive Vice President, Head of Business Development | ||
| Sandra Beaty, Executive Vice President - Corporate Affairs | ||
| Robert Kelly, Executive Vice President and President International Operations | ||
| J McFarland, Executive Vice President and Chief Medical Officer | ||
| Robert Polzer, Executive Vice President and Presidentident of Research and Development | ||
| William Doyle, Director | ||
| Andrew Fenton, Executive Vice President and Chief Digital and Technology Officer | ||
| Gregory Norden, Independent Director | ||
| Louise Parent, Independent Director | ||
| Heidi Chen, Executive Vice President General Counsel, Corporate Secretary | ||
| Abhay Nayak, Executive Vice President Head of Strategy and Accelerated Growth Businesses | ||
| Juan Alaix, Chief Executive Officer, Director |
Zoetis Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Zoetis a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.5 | ||||
| Return On Asset | 0.13 | ||||
| Profit Margin | 0.27 % | ||||
| Operating Margin | 0.32 % | ||||
| Current Valuation | 73.37 B | ||||
| Shares Outstanding | 456.95 M | ||||
| Shares Owned By Insiders | 0.23 % | ||||
| Shares Owned By Institutions | 95.60 % | ||||
| Number Of Shares Shorted | 3.65 M | ||||
| Price To Earning | 43.89 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Zoetis Inc is a strong investment it is important to analyze Zoetis' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Zoetis' future performance. For an informed investment choice regarding Zoetis Stock, refer to the following important reports:Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zoetis Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Complementary Tools for Zoetis Stock analysis
When running Zoetis' price analysis, check to measure Zoetis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Zoetis is operating at the current time. Most of Zoetis' value examination focuses on studying past and present price action to predict the probability of Zoetis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Zoetis' price. Additionally, you may evaluate how the addition of Zoetis to your portfolios can decrease your overall portfolio volatility.
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data |
Is Zoetis' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zoetis. If investors know Zoetis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zoetis listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.164 | Dividend Share 1.5 | Earnings Share 5.06 | Revenue Per Share 18.527 | Quarterly Revenue Growth 0.085 |
The market value of Zoetis Inc is measured differently than its book value, which is the value of Zoetis that is recorded on the company's balance sheet. Investors also form their own opinion of Zoetis' value that differs from its market value or its book value, called intrinsic value, which is Zoetis' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zoetis' market value can be influenced by many factors that don't directly affect Zoetis' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zoetis' value and its price as these two are different measures arrived at by different means. Investors typically determine if Zoetis is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zoetis' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.